West Pharmaceutical Services (WST) Share-based Compensation (2009 - 2026)

West Pharmaceutical Services has disclosed Share-based Compensation across 18 years of filings, most recently posting $10.9 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 47.3% year-over-year to $10.9 million; the TTM figure through Jun 2026 stood at $32.6 million (up 68.91% YoY), while the FY2025 annual figure was $23.8 million, up 27.27% from the prior year.
• Share-based Compensation came in at $10.9 million for Q2 2026 at West Pharmaceutical Services, up from $6.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $18.8 million in Q1 2022 to a low of $1.4 million in Q4 2023.
• Average Share-based Compensation over 5 years is $6.8 million, with a median of $5.9 million recorded in 2022.
• Year-over-year, Share-based Compensation tumbled 67.44% in 2023 and soared 207.14% in 2024.
• Over 5 years, Share-based Compensation stood at $4.3 million in 2022, then plunged by 67.44% to $1.4 million in 2023, then soared by 207.14% to $4.3 million in 2024, then soared by 55.81% to $6.7 million in 2025, then soared by 62.69% to $10.9 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $10.9 million in Q2 2026, $6.6 million in Q1 2026, and $6.7 million in Q4 2025.